Research and Markets: Lip and Oral Cavity Cancer Therapeutics - Market is Forecast to Show Steady Growth until 2018 to reach $142.52m

DUBLIN--()--Research and Markets(http://www.researchandmarkets.com/research/ad208b/lip_and_oral_cavit) has announced the addition of GlobalData's new report "Lip and Oral Cavity Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2018" to their offering.

GlobalData, the industry analysis specialist, has released its new report, Lip and Oral Cavity Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2018. The report is an essential source of information and analysis on the global Lip and Oral Cavity Cancer Therapeutics market. The report identifies the key trends shaping and driving the global Lip and Oral Cavity Cancer Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Lip and Oral Cavity Cancer Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

The Lip and Oral Cavity Cancer Therapeutics Market is Forecast to Show Steady Growth until 2018

GlobalData estimates that the global (the seven key markets of the US, the UK, Germany, Italy, France, Spain and Japan) lip and oral cavity cancer therapeutics market was worth $114.79m in 2010 and forecasts it to grow at a Compound Annual Growth Rate (CAGR) of 2.7% to reach $142.52m by 2018. The existing market is strong, and is represented by two approved products, Erbitux and Taxotere, of which only the former is patent protected. Erbitux is currently approved in the US and European Union (EU) but not in Japan. The growth during 2005-2010 is primarily attributed to the launch of Taxotere and Erbitux for the treatment of Squamous Cell Carcinoma of the Head and Neck (SCCHN).

Key Topics Covered:

  • List of Tables and Figures
  • Lip and Oral Cavity Cancer Therapeutics - Introduction
  • Lip and Oral Cavity Cancer Therapeutics - Market Characterization
  • Lip and Oral Cavity Cancer Therapeutics Market - Competitive Assessment
  • Lip and Oral Cavity Cancer Therapeutics Market - Pipeline Assessment
  • Lip and Oral Cavity Cancer Therapeutics - Clinical Trials Mapping
  • Lip and Oral Cavity Cancer Therapeutics - Strategic Assessment
  • Global Lip and Oral Cavity Cancer Therapeutics - Future Players
  • Lip and Oral Cavity Cancer Therapeutics - Appendix

For more information visit http://www.researchandmarkets.com/research/ad208b/lip_and_oral_cavit

Contacts

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Contacts

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716